{"id":"W3173401695","doi":"10.1158/1078-0432.ccr-21-0809","title":"5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":182,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Vemurafenib; Medicine; Placebo; Internal medicine; Melanoma; Gastroenterology; Surgery; Metastatic melanoma; Pathology; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012649,0.000161328,0.0004151644,0.00004879119,0.0001149048,0.00002316947,0.0004175892,0.0001549217,0.00006549017],"category_scores_gemma":[0.0008297827,0.000110457,0.0001616965,0.0004530596,0.0003585425,0.000006792844,0.000381615,0.0004908657,0.00000852724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004270151,"about_ca_system_score_gemma":0.001181308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001535172,"about_ca_topic_score_gemma":0.003920009,"domain_scores_codex":[0.9968526,0.001050808,0.0005422798,0.0006223972,0.0005375666,0.0003943307],"domain_scores_gemma":[0.9981136,0.0003366299,0.0001299244,0.0006841945,0.0006142979,0.0001213131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003410694,0.001838051,0.9442267,0.00007029144,0.000402222,0.0002291976,0.0008137942,0.00007468402,0.04060412,0.0002269085,0.0006065638,0.00749678],"study_design_scores_gemma":[0.01345077,0.002171345,0.8807979,0.00008479595,0.00004193392,0.000007860197,0.002206306,0.00001052235,0.09946365,0.00005041688,0.001491461,0.0002231029],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965411,0.0006368361,0.00003244032,0.0003488047,0.0003177877,0.0008168751,0.00007059364,0.000006155453,0.0012294],"genre_scores_gemma":[0.9958432,0.0001362072,0.000171358,0.0001626468,0.0001002708,0.0001939426,0.00003989774,0.00002814316,0.003324275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06342886,"threshold_uncertainty_score":0.4504305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0778736949624746,"score_gpt":0.4348568937526744,"score_spread":0.3569831987901998,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}